BioAge Labs, Inc.
BIOANasdaqCIK 1709941HealthcareFiscal year ends Dec 31
Reports and events: 32 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-0220:15 ET | 8-K | 8.01 Other events | 0001193125-26-412300 |
| 2026-08-0521:00 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-335407 |
| 2026-08-0520:55 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335368 |
| 2026-06-1212:00 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-268518 |
| 2026-05-0813:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-213472 |
| 2026-05-0813:05 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-213466 |
| 2026-04-2120:05 ET | DEF 14A | Proxy statementPeriod 2026-06-10 | 0001193125-26-166738 |
| 2026-03-2413:15 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-120873 |
| 2026-03-2413:10 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-120864 |
| 2026-01-2221:34 ET | 8-K | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-019536 |
| 2026-01-2014:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-016046 |
| 2026-01-1214:10 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-009911 |
| 2025-12-0414:05 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-307541 |
| 2025-11-0621:55 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-270012 |
| 2025-11-0621:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-269986 |
| 2025-08-0620:45 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104176 |
| 2025-08-0620:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104151 |
| 2025-06-0920:15 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-083746 |
| 2025-06-0413:00 ET | 8-K | 8.01 Other events | 0000950170-25-081409 |
| 2025-05-0620:40 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-064552 |
| 2025-05-0620:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-064547 |
| 2025-04-1720:05 ET | DEF 14A | Proxy statementPeriod 2025-06-05 | 0000950170-25-055371 |
| 2025-03-2021:04 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-042759 |
| 2025-03-2020:54 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-042747 |
| 2024-11-0721:40 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-123445 |
| 2024-11-0721:35 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-123437 |
| 2024-10-0400:21 ET | SC 13D | Ownership report, active investor | 0001104659-24-106374 |
| 2024-09-3000:34 ET | SC 13D | Ownership report, active investor | 0001104659-24-104494 |
| 2024-09-2720:05 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-24-227949 |
| 2024-09-2510:06 ET | S-1/A | Registration statement, amended | 0001193125-24-225155 |
| 2024-09-1820:04 ET | S-1/A | Registration statement, amended | 0001193125-24-221367 |
| 2024-09-0320:02 ET | S-1 | Registration statement | 0001193125-24-212046 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.